

# We're tackling cancer head-on.

At Mirati, we convert possibility into reality by developing **best-in-class targeted therapies** to improve the lives of patients.


Investors & Media Careers Contact Us
Home Science Patients Impact About

**Our Programs** 

Display a menu



Investors & Media Careers Contact Us me Science Patients Impact About




## KRAS

Our scientists are rigorously advancing research and development programs targeting the KRAS G12C and KRAS G12D mutations.



Explore our KRAS programs



# Sitravatinib


We are exploring new ways of targeting the protective nest of cells, tissues and blood vessels that make up the tumor microenvironment.



Mirati is developing a pipeline of novel therapeutics.

**Explore the Pipeline** 







# **Press Releases**

#### 05/06/2021

Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates >

### 04/19/2021



Stand Up to Cancer Announces \$4 Million Grant From Mirati Therapeutics to Support Research on KRAS Mutant Cancers >

## 04/10/2021

Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models >

## 03/31/2021

Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director >



in



© Copyright 2021 - Mirati Therapeutics, Inc. 858.332.3410 | info@mirati.com

Terms of Use | Privacy Policy | Cookies Policy | Expanded Access Policy

